<DOC>
	<DOCNO>NCT00006617</DOCNO>
	<brief_summary>The purpose study see multidrug combination zidovudine ( ZDV ) , lamivudine ( 3TC ) , 1592U89 ( abacavir [ ABC ] ) , 141W94 ( amprenavir [ APV ] ) safe effective treatment HIV-infected patient reduction active HIV blood tissue . HIV infection life-changing illness new HIV treatment must test . This study test 4-drug combination reduce HIV virus activity blood tissue safe well tolerate . Doctors also want know multidrug combination able decrease viral activity long time period .</brief_summary>
	<brief_title>Four-Drug Combination Therapy With Zidovudine , Lamivudine , 1592U89 ( Abacavir ) , 141W94 ( Amprenavir ) HIV-Infected Patients</brief_title>
	<detailed_description>With effective combination ART , decrease HIV-1 RNA plasma 2 3 week . A second , slow phase viral decay think occur long-lived macrophage , minimal contribution lymphocytes . This study address whether third reservoir central nervous system . Additionally , study aim provide good understand type length ART require suppress HIV-1 replication multiple reservoir . Patients receive treatment ZDV , 3TC , ABC , APV daily 24 week . Clinic visit occur weekly Week 4 , every 2 week Week 12 , monthly . Blood urine sample collect patient monitor clinical laboratory abnormality . Laboratory test assess side effect virologic immunologic parameter , include viral quantification CSF chronically infect patient select consent acutely infected patient , determine . In pharmacoeconomic component study , patient interview complete questionnaire 5 clinic visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 18 year old . Have chronic ( longterm ) HIV infection ( great 90 day ) recent HIV infection . Have plasma viral load ( level HIV blood ) least 5,000 copies/ml ( chronically infect patient ) . Are able follow study requirement . Agree practice reliable form birth control barrier surgical method , start 1 month prior entry enrol study . Exclusion Criteria Patients eligible study : Have prior antiHIV treatment ( recently infect patient ) . Have history bloodclotting problem . Have ever receive treatment protease inhibitor 3TC . Are high risk develop infection heart . Are critically ill. Are mentally disabled , prisoner , confine institution . Are breastfeed pregnant . Have gastrointestinal problem might interfere drug absorption unable take medicine mouth . Need regular blood transfusion . Have unexplained fever high 38.5 C 14 day within 30 day enrollment . Have opportunistic ( AIDSrelated ) infection require treatment ( treatment must complete 30 day start study ) . Are take certain medication may interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lymphoid Tissue</keyword>
	<keyword>Gastrointestinal System</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Lymphocyte Subsets</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Cerebrospinal Fluid</keyword>
	<keyword>abacavir</keyword>
</DOC>